A phenotypic plethora of exclusively cutaneous adverse events following immunisation (AEFI) with COVID‐19 vaccines have been described. Currently, there is no formal consensus on advice given to affected individuals, pertaining to their subsequent COVID‐19 vaccines, which is increasingly pertinent as countries such as the United Kingdom launch a further booster phase of the COVID‐19 mass vaccination program due to concerns over waning immunity from initial vaccinations.
Phenotypic spectrum of serious cutaneous only adverse event following immunisation with COVID‐19 vaccines: a multi‐centre case series and literature review